Immucell (ICCC) Free Cash Flow (2010 - 2025)
Immucell's (ICCC) quarterly Free Cash Flow came in at $1.6 million in Q4 2025, up 493.81% YoY from $262037.0 in Q4 2024, and up 187.59% on a QoQ basis from -$1.8 million in Q3 2025.
Immucell (ICCC) Free Cash Flow (2010 - 2025) Analysis & Trends
Immucell (ICCC) has 16 years of Free Cash Flow data on file, last reported at $1.6 million in Q4 2025.
- Quarterly Free Cash Flow rose 493.81% year-over-year to $1.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (up 598.93% YoY) and the FY2025 annual result came in at $2.5 million, up 598.93% from the prior year.
- Free Cash Flow advanced to $1.6 million in Q4 2025, from -$1.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $1.6 million in Q4 2025 to a low of -$3.4 million in Q1 2023.
- A 5-year average of -$545814.2 and a median of -$493120.5 in 2021 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow slumped 2289.01% — and 2025, when it soared 493.81%.
- Tracing ICCC's Free Cash Flow over 5 years: stood at -$116701.0 in 2021, then tumbled by 2289.01% to -$2.8 million in 2022, then soared by 71.15% to -$804415.0 in 2023, then soared by 132.57% to $262037.0 in 2024, then soared by 493.81% to $1.6 million in 2025.
- The last three Free Cash Flow figures came in at $1.6 million (Q4 2025), -$1.8 million (Q3 2025), and $1.4 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Immucell | 91.19 Mn | 82.33 Mn | 2.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.56 Mn |
| Dec 31, 2025 | 1.56 Mn |
| Sep 30, 2025 | -1.78 Mn |
| Sep 30, 2025 | -1.78 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 262,037.00 |
| Dec 31, 2024 | 262,037.00 |
| Sep 30, 2024 | -727,743.00 |
| Sep 30, 2024 | -727,743.00 |
| Jun 30, 2024 | 471,039.00 |
| Jun 30, 2024 | 471,039.00 |
| Mar 31, 2024 | 348,149.00 |
| Mar 31, 2024 | 348,149.00 |
| Dec 31, 2023 | -804,415.00 |
| Dec 31, 2023 | -804,415.00 |
| Sep 30, 2023 | -928,269.00 |
| Sep 30, 2023 | -928,269.00 |